Related Experiment Video

Updated: Jul 18, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Novel treatment strategies for chronic myeloid leukemia

Christopher A Fausel1

  • 1Hematology/Oncology/Bone Marrow Transplant, Indiana University Cancer Center, Indianapolis, IN 46202, USA. cfausel@clarian.org

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|November 16, 2006
PubMed
Abstract

Insights

New kinase inhibitors like dasatinib and nilotinib show promise for treating chronic myeloid leukemia (CML) resistant to imatinib. These targeted therapies effectively inhibit BCR-ABL mutations, offering new hope for CML patients.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Chronic myeloid leukemia (CML) treatment advances face challenges due to therapeutic agent resistance.
  • BCR-ABL kinase domain mutations are a primary cause of imatinib resistance in CML.

Purpose of the Study:

  • To discuss BCR-ABL kinase domain mutations as a mechanism of imatinib resistance in CML.
  • To review emerging targeted therapies for imatinib-refractory CML.

Main Methods:

  • Review of clinical trial data for new kinase inhibitors.
  • Comparative analysis of imatinib, dasatinib, and nilotinib efficacy and potency.
  • Investigation of other therapeutic strategies including farnesyl transferase inhibitors and vaccination.

Main Results:

  • Dasatinib and nilotinib demonstrate significantly higher potency than imatinib against BCR-ABL.
  • These agents are effective in chronic phase CML but show reduced efficacy in accelerated phase CML.
  • Farnesyl transferase inhibitors and vaccination strategies are under active clinical investigation.

Conclusions:

  • Dasatinib and nilotinib represent viable therapeutic options for CML patients resistant to imatinib.
  • Targeted kinase inhibitors offer a promising approach to overcome BCR-ABL-mediated resistance.
  • Ongoing research into novel therapies like farnesyl transferase inhibitors and vaccines may further improve CML treatment outcomes.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...